Sanofi (OTCMKTS:SNYNF – Get Rating) was the recipient of a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 1,243,300 shares, a decline of 20.7% from the April 15th total of 1,567,400 shares. Based on an average trading volume of 4,300 shares, the short-interest ratio is currently 289.1 days.
Separately, Stifel Nicolaus began coverage on shares of Sanofi in a research report on Monday, February 28th. They set a “buy” rating and a $120.00 price objective for the company.
Shares of OTCMKTS SNYNF opened at $101.58 on Monday. Sanofi has a 52-week low of $92.01 and a 52-week high of $115.37. The firm has a 50 day moving average price of $105.10 and a two-hundred day moving average price of $102.74.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNYNF)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.